58 results about "Eicosatetraenoic acid" patented technology

The present invention relates to fatty acid desaturases and elongases able to catalyze the conversion of linoleic acid (LA) to γ-linolenic acid (GLA); α-linoleic acid (ALA) to stearidonic acid (STA); GLA to dihomo-γ-linoleic acid (DGLA); STA to eicosatetraenoic acid (ETA); DGLA to ETA; eicosapentaenoic acid (EPA) to docosapentaenoic acid (DPA); and arachidonic acid (ARA) to EPA. Nucleic acid sequences encoding codon-optimized desaturases and elongases, nucleic acid sequences which hybridize thereto, DNA constructs comprising the codon-optimized desaturase or elongases, and recombinant host microorganisms expressing increased levels of desaturase or elongase are described.

The production and use, and in particular, the extraction, separation, synthesis and recovery of polar lipid-rich fractions containing eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), docosapentaenoic acid (DPA(n-3) or DPA(n-6)), arachidonic acid (ARA), and eicosatetraneonoic acid (C20:4n-3) from microorganisms, genetically modified seeds and marine organisms (including fish and squid) and their use in human food applications, animal feed, pharmaceutical applications and cosmetic applications.

The present invention relates to mutant Δ5 desaturases, which have the ability to convert dihomo-γ-linolenic acid [DGLA; 20:3 ω-6] to arachidonic acid [ARA; 20:4 ω-6] and/or eicosatetraenoic acid [ETA; 20:4 ω-3] to eicosapentaenoic acid [EPA; 20:5 ω-3] and which possess at least one mutation within the HPGG motif of the cytochrome b₅-like domain. Isolated nucleic acid fragments and recombinant constructs comprising such fragments encoding Δ5 desaturases, along with a method of making long chain polyunsaturated fatty acids [“PUFAs”] using these mutant Δ5 desaturases in oleaginous yeast, are disclosed.

The invention discloses an infant formula added with combined prebiotics and a preparation method thereof, and relates to the technical field of dairy processing; the infant formula is prepared from, by weight percent, 92-98% of base powder, 0-0.5% of concentrated whey protein, 0.1-0.35% of casein phosphopeptides, 0.22-1.1% of docosahexaenoic acid, 0.25-1.0% of eicosatetraenoic acid, 0.3-0.5% of composite vitamin, 0.15-0.2% of mineral substance, 0.25-0.3% of calcium carbonate, 0.1-0.2% of tricalcium phosphate, 0.02-0.05% of nucleotide, 0.3-0.5% of choline chloride, and 0.5-6.4% of combined prebiotics. The combined prebiotics contained the milk powder can promote the growth and breeding of bifidobacterium or lactobacillus and other probiotics in the intestinal tract, and improve microenvironment of intestinal tract, and is good for maintaining normal intestinal tract function, and has the similar effect of oligosaccharide of breast milk.

The present invention relates to an infant formula milk powder and a preparation method thereof. Hydrolyzed whey protein powder, nucleotides and lactoferrin are added in the infant formula milk powder based on the original infant milk powder, and the infant formula milk powder is prepared by using a dry mixing method. The beneficial effects of the infant formula milk powder are that the hydrolyzed whey protein powder, nucleotides and lactoferrin are added into the infant milk powder to enable the infant milk powder to be closer to breast milk and to enhance the resistance of infants. Docosahexaenoic acids and eicosatetraenoic acids in the milk powder are essential for infant mental and visual developments. The drying process avoids the heat of nutritional enhancer, prevents the destruction of heat-sensitive components, and thus ensures the nutrition and function of the product and enables the milk powder to be more conducive to digestion, absorption, and organism protection of infants.

The invention relates to a nutritional composition comprising (a) at least 18 en% of proteinaceous matter; (b) at least 12 wt% of leucine, based on total proteinaceous matter: (C) a lipid fraction comprising at least an omega-3 polyunsaturated fatty acid selected from the group of eicosapentaenoic acid, docosahexaenoic acid, eicosatetraenoic acid and docosapentaenoic acid; and (d) an immune modulator; for improving the immune function in a mammal, preferably a human.

The invention discloses an algal soft capsule containing arachidonic acid. The soft capsule mainly contains following active ingredients: algal oil (containing DHA (docosahexenoic acid) and free from EPA), arachidonic acid (AA (eicosatetraenoic acid)), lecithin (PC (phosphatidylcholine)) and vitamin E, as well as auxiliary materials such as water, glycerol and edible animal gelatin. According to the algal oil soft capsule disclosed by the invention, multiple nutrient substances, namely, DHA, AA and PC, important for brain growth and development are effectively combined, and the ingredients are further coordinated to play the roles of improving memory, eliminating brain fatigue, and enhancing concentration and attention. Moreover, the algal oil soft capsule is safe and reliable, and free from EPA ingredient which can promote premature of children.

The invention discloses broken-wall spirulina milk powder. According to the formula, the broken-wall spirulina milk powder consists of the following raw materials in parts by weight: 400-600 parts of fresh milk, 20-40 parts (4.4-5.6%) of spirulina, 4-10 parts (0.9-1.4%) of concentrated whey protein powder, 1-6 parts of walnut oil, 1-6 parts of soy isolate protein, 1-6 parts of apricot kernel powder, 10-20 parts of fruit and vegetable cellulose powder, 2-8 parts of fructo-oligosaccharide, 2-8 parts of deep sea fish oil, 2-8 parts of a beta-linoleic growth repair factor, 0.2-0.6 part of docosahexaenoic acid, 0.4-0.8 part of eicosatetraenoic acid, 0.1-0.5 part of complex vitamin and 0.2-0.5 part of complex trace element. The broken-wall spirulina milk powder disclosed by the invention can be used for boosting the immunity of a mother, enhancing the health of the mother and benefiting healthy development of a fetus.

The invention relates to a milk powder capable of improving the infant's immunity. The milk powder is composed of the following raw materials in parts by weight: 600 to 800 parts of high-oil desalted whey powder, 100 to 200 parts of whole milk powder, 3 to 5 parts of hydrolyzed whey protein powder, 1 to 3 parts of whey protein powder, 2 to 5 parts of galactooligosaccharide, 1 to 3 parts of fructo-oligosaccharide, 1 to 3 part of docosahexaenoic acid (DHA), 1 to 3 parts of eicosatetraenoic acid (ETA) 0.4 to 1 part of lactoferrin, 0.05 to 0.07 part of bifidobacterium, 3 to 6 parts of multi-vitamins, and 2 to 7 parts of composite mineral substances. The milk powder can provide enough nutrients for the growth of infants, can be easily absorbed by the infants, and is capable of improving the infant's immunity and reducing the phenomenon of excessive internal heat, diarrhea, or constipation caused by dyspepsia. The milk powder is produced through a dry-mixing technology, thus the loss of active substances (EHA, ETA, etc.) during the process of wet process addition is avoided, and the activity loss of lactoferrin and bifidobacterium in the wet process addition is maximally reduced.

Leukotriene B₄, 5S,12R-dihydroxy-6,8,10,14(Z,E,E,Z)-eicosatetraenoic acid, is a twenty carbon tetra-unsaturated fatty acid. No crystal forms of leukotriene B₄ (LTB₄) are known in the art. The present inventors have discovered a crystal form of LTB₄ and the present invention therefore relates to crystal forms of LTB₄ in general, and the novel crystal form A of LTB₄ in particular.

The invention discloses formula milk powder for infant of one to three years old. The raw materials of the milk powder per ton comprise: 585 to 610 kg of base powder, 176 to 198 kg of demineralized whey powder, 128 to 145 kg of dried skim milk, 22 to 27 kg of whole milk powder, 18.5 to 21 kg of concentrated whey protein powder, 14.5 to 18 kg of hydrolyzed whey protein powder, 1.8 to 2.5 kg of eicosatetraenoic acid, 1.5 to 2.0 kg of docosahexaenoic acid, and 7.7 to 12.5 kg of compound nutrition enhancer. The base powder is mixed with added components to facilitate control over on the basic components of the milk powder, and the basic components can be elastically adjusted as required subsequently. A protein structure can be modified by using the hydrolyzed whey protein powder, so that the quantity of antigen active substances is greatly reduced, and the outbreak of infant's atopic dermatitis is reduced.

The invention discloses a novel serum lipid metabolite composition and application of the serum lipid metabolite composition as a marker in preparation of a non-smoking female lung cancer diagnostic kit. The serum lipid metabolite composition comprises eicosadienoic acid FA C20:2, eicosatetraenoic acid FA C20:4, tetracosatetraenoic acid FA C24:4, phosphatidylcholine PC 20:1/22:6, phosphatidylinositol PI18:0/20:5 and phosphatidyl ethanolamine PE18:0p/22:4. The serum lipid metabolite composition can be used for auxiliary diagnosis of non-smoking female lung cancer, and has the characteristics of low detection cost, good repeatability, and high sensitivity and specificity. Meanwhile, the lipid metabolite composition also has a good effect on diagnosis of early-stage lung cancer of non-smoking females.

The invention discloses a method for extracting unsaturated fatty acid from an Asia grateloupia filicina. The method comprises the following steps: washing Asia grateloupia filicina clean; adding a composite cellulase according to the mass ratio of 1:100 and acting at the temperature of 50 DEG C for 2h; draining, drying and smashing to obtain the grateloupia filicina powder; adding the grateloupia filicina powder into petroleum ether, soaking for 24h, performing water bath backflow, filtering and centrifuging to obtain supernate; adding a saponified solution to the supernate, adding a hydrochloric acid solution by the end of saponification, and adjusting the PH value to 3.4-4 to obtain the unsaturated fatty acid. The gas chromatography shows that in the unsaturated fatty acid extracted from the grateloupia filicina pretreated by the composite cellulase, the content of timnodonic acid (C20:5) and eicosatetraenoic acid (C20:4) is greater than 75% of the total unsaturated fatty acid and is about 50% higher than that of the direct extraction process. A method for efficiently extracting the unsaturated fatty acid from the Asia grateloupia filicina is established for the first time and a scientific basis for the efficient comprehensive utilization of Asia grateloupia filicina is provided.

The present invention relates to milk powder for promoting absorption of infants and young children and a preparation method thereof. The product comprises 400-600 parts of fresh milk, 20-40 parts ofdesalted whey powder, 4-10 parts of concentrated whey protein powder, 4-10 parts of n-3 polyunsaturated fatty acids, 10-15 parts of n-6 polyunsaturated fatty acids, 1-6 parts of walnut oil, 1-5 partsof lutein crystals, 4-10 parts of biological growth factors, 6x10<6>-15x10<6> of active bifidobacterium longum, 4-10 parts of bifidobacterium multiplication factors, 2-8 parts of fructo-oligosaccharides, 0.2-0.6 part of docosahexaenoic acid, 0.4-0.8 part of eicosatetraenoic acid, 1-5 parts of compound fruit and vegetable powder, 0.06-0.1 part of choline, 0.03-0.05 part of taurine, 0.1-0.5 part ofmultivitamin and 0.2-0.5 part of compound trace elements. Due to the presence of the active bifidobacterium longum, the active bifidobacterium longum can effectively improve intestinal flora distribution of the infants, promote absorption of nutrients by the infants and young children, and improve immunity of the infants and young children.